Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1/2, Open-Label, Safety, Tolerability, and Efficacy Study of Epacadostat in Combination With Pembrolizumab and Chemotherapy in Subjects With Advanced or Metastatic Solid Tumors (ECHO-207/KEYNOTE-723)

Trial Profile

A Phase 1/2, Open-Label, Safety, Tolerability, and Efficacy Study of Epacadostat in Combination With Pembrolizumab and Chemotherapy in Subjects With Advanced or Metastatic Solid Tumors (ECHO-207/KEYNOTE-723)

Active, no longer recruiting
Phase of Trial: Phase I/II

Latest Information Update: 16 Nov 2018

At a glance

  • Drugs Epacadostat (Primary) ; Pembrolizumab (Primary) ; Carboplatin; Cyclophosphamide; Fluorouracil; Folinic acid; Gemcitabine; Oxaliplatin; Paclitaxel; Pemetrexed
  • Indications Solid tumours
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms ECHO-207
  • Sponsors Incyte Corporation
  • Most Recent Events

    • 16 Nov 2018 This trial was discontinued in Spain.
    • 05 Nov 2018 Planned End Date changed from 1 Oct 2022 to 1 Jan 2020.
    • 05 Nov 2018 Planned primary completion date changed from 1 Apr 2021 to 1 Oct 2019.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top